Hypotonic riboflavin
Phase 3Small molecule
Hypotonic riboflavin is one of 11 small molecule programs targeting Keratoconus. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Keratoconus
#DrugCompanyPhaseTrials
1Neurontin
VViatris Specialty LLC
Approved
Toradol
JJavelin Pharmaceuticals
Approved
Decadron
AAspen Global Incorporated
Approved
Mitosol
UUroGen Pharma Ltd.
Approved
Pred Forte
NovartisPhase 1
Ricrolin+
IIcahn School of Medicine at Mount Sinai
Phase 3
Hypotonic riboflavin
CCornea and Laser Eye Institute
Phase 3
Neoral
NovartisPreclinical
Riboflavin
CCornea and Laser Eye Institute
Preclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hypotonic riboflavin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCornea and Laser Eye Institute